摘要
本研究旨在评估增殖相关抗原Ki-67在弥漫大B细胞淋巴瘤(DLBCL)中的表达及临床意义。回顾性分析了2008年1月至2010年12月在我院确诊DLBCL的50例患者的Ki-67表达水平及其与预后的关系。结果显示,Ki-67的表达水平与患者的年龄、性别、分期、有无B症状、LDH水平、IPI危险度分组、结外受累病灶数、是否为巨块型、有无骨髓受累、是否为生发中心来源、治疗方案以及初始治疗反应均无显著相关。Ki-67低表达组(<85%)和高表达组(≥85%)患者的中位生存时间分别为50个月和15个月。Ki-67低表达组患者的总体生存期(OS)和无进展生存(PFS)期均显著优于高表达组(P=0.001;P=0.027)。单因素分析显示,影响OS的临床因素包括Ann Arbor分期和Ki-67表达水平,影响PFS的临床因素包括Ann Arbor分期、IPI评分及Ki-67表达水平。多因素分析显示,Ki-67表达水平是影响OS的独立预后因素(HR=4.90;95%CI,1.456-16.511;P=0.0103)。结论:增殖相关抗原Ki-67是判断DLBCL预后的有效指标。
This study was aimed to evaluate the proliferation-associated antigen Ki-67 expression in dffuse large B cell lymphoma （DLBCL） and its clinical significance. The Ki-67 expression and its correlation with prognosis in 50 patients with DLBCL treated with rituximab plus CHOP （R-CHOP） between January 2008 and December 2010 were analyzed retrospectively. The results indicated that there was no significant relationship between Ki-67 expression and clinical features, including age, sex, staging, B symptoms, LDH level, IPI, extranodal site involvement, presence of bulky tumors （ 〉 10 cm in diameter）, bone marrow involvement, GCG nor GCB type, or response to firstline treatment. The median survival was 50 months and 15 months in low Ki-67 expression group （ 〈 85% ） and in high Ki- 67 expression group （≥ 85% ） respectively. The overall survival（ OS ） and progress-free survival（ PFS ） in low Ki-67 expression group were obviously longer than that in high Ki-67 expression group （P = 0. 001 ;P = 0. 027 ）. In univariate analysis, the clinical factors associated with OS included Ann Arbor staging and Ki-67 expression. The clinical factors associated with PFS included Ann Arbor staging. IPI and Ki-67 expression. In multivariate analysis. The Ki-67 expression level was an independent prognostic factor for OS （HR = 4. 90;95% CI,1. 456 - 16. 511 ;P = 0. 0103）. It is concluded that Ki-67 expression level seems to be an effective marker for evaluation of DLBCL prognosis.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2013年第5期1162-1166,共5页
Journal of Experimental Hematology
